How to buy Clovis Oncology stock (CLVS)

Clovis Oncology is a biotechnology & medical research business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 413 staff and has a trailing 12-month revenue of around $133 million.

Our top picks for where to buy Clovis Oncology stock

Buy Clovis Oncology stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Clovis Oncology stock price (NASDAQ: CLVS)

Use our graph to track the performance of CLVS stocks over time.

Clovis Oncology shares at a glance

• Key figures

Information last updated 2023-02-26.

52-week range	$0.00 - $0.00
50-day moving average more info button	$0.41
200-day moving average more info button	$1.22
Wall St. target price	$2.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-2.08

Is it a good time to buy Clovis Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Clovis Oncology stock undervalued or overvalued?

Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Clovis Oncology's PEG ratio

Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Clovis Oncology financials

Revenue TTM	$133 million
Gross profit TTM	$115.3 million
Return on assets TTM	-30.18%
Return on equity TTM	0%
Profit margin	-189.38%
Book value	$-2.89
Market Capitalization more info button	$11.8 million

TTM: trailing 12 months

Clovis Oncology share dividends

We're not expecting Clovis Oncology to pay a dividend over the next 12 months.

Clovis Oncology share price volatility

Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 0.2205. This would suggest that Clovis Oncology's shares are less volatile than average (for this exchange).

Clovis Oncology overview

Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U. S. , the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein.

Frequently asked questions

null
What percentage of Clovis Oncology is owned by insiders or institutions?
Currently 1.438% of Clovis Oncology shares are held by insiders and 25.898% by institutions. How many people work for Clovis Oncology?
Latest data suggests 413 work at Clovis Oncology. When does the fiscal year end for Clovis Oncology?
Clovis Oncology's fiscal year ends in December. Where is Clovis Oncology based?
Clovis Oncology's address is: 5500 Flatiron Parkway, Boulder, CO, United States, 80301 What is Clovis Oncology's ISIN number?
Clovis Oncology's international securities identification number is: US1894641000 What is Clovis Oncology's CUSIP number?
Clovis Oncology's Committee on Uniform Securities Identification Procedures number is: 189464100